Abstract:Transforming growth factor-b (TGF-b) was initially discovered by its ability to stimulate immortalized fibroblasts to grow in soft agar, a phenotype associated with expressing cancer-causing genes. Subsequently, it became clear that the ‘‘transforming activity’’ of TGF-b is reversible and can have potent cytostatic effects on normal epithelial cells. TGF-b is now well known for its dual effects in cancer progression; while TGF-b can have suppressive effects on normal and premalignant cells, more advanced cancer cells—frequently exposed to high levels of TGF-b produced by themselves or the stroma—are not only resistant to its cytostatic effects but also stimulated in their invasive and metastatic behavior. TGF-b can do this directly by facilitating epithelial tomesenchymal transition (EMT) and indirectly by acting on its surrounding stroma, promoting angiogenesis and immune evasion (Akhurst and Derynck, 2001). TGF-b signals via cell surface TGF-b type I and type II serine threonine kinase receptors and intracellular SMAD effector proteins. Upon TGF-b receptor activation, SMAD2 and SMAD3 become phosphorylated and form heteromeric complexes with SMAD4. These SMAD complexes can accumulate in the nucleus, where they act as transcriptional regulators. Because SMAD2 does not interact with DNA and the affinity of SMAD3 and SMAD4 for DNA is weak, there is a need for SMADs to partner with other DNAbinding transcription factors. The repertoire of SMAD interaction partners is large and diverse, providing a basis for multi-functionality of TGF-b and its context-dependent effects (Massagué, 2012). TGF-b receptors and SMADs are mutated in certain cancers. Inactivation of tumor suppressor genes, activation of proto-oncogenes, and microenvironmental changes can change the tumor suppressive and the tumor promoting activity of the TGF-b receptor/SMAD pathway. Most cancer patients die of metastasis and, because TGF-b is a strong driver of this process, TGF-b pathway inhibiting agents have been developed and tested in clinical trials. However, these compounds inhibit all TGF-b responses and may elicit unwanted effects. Careful selection of patients is warranted and proper biomarkers are needed to select those patients that will benefit from such systemic TGF-b-targeted therapy. A better understanding of the molecular mechanisms underlying the contextual effects of TGF-b in cancer may allow development of therapeutics selectively inhibiting its pro-oncogenic effects. Previously, Yu and colleagues provided some clues on these mechanisms by demonstrating that the phosphoserine/phosphothreonine-binding protein 14-3-3z, which is overexpressed in more than 40% of breast cancers, can potentiate TGF-b/ SMAD signaling during EMT and breast tumor progression (Lu et al., 2009). 14-33z and the tyrosine kinase receptor ErbB2 were found to cooperate in driving non-invasive ductal carcinoma in situ (DCIS) progression to invasive breast ductal carcinoma (IDC). Breast tumors expressing both ErbB2 and 14-3-3z have a higher incidence of metastasis than those expressing only one of them (Lu et al., 2009). In addition, they found 143-3z downregulated the cell cycle inhibitor p27 and activated phosphoinositide 3-kinase, thereby promoting cancer cell proliferation and survival (Rehman et al., 2014 and references therein).

JNK-Dependent cJun Phosphorylation Mitigates TGFβ- and EGF-Induced Pre-Malignant Breast Cancer Cell Invasion by Suppressing AP-1-Mediated Transcriptional Responses.

Sustained C-Jun-nh2-kinase Activity Promotes Epithelial-Mesenchymal Transition, Invasion, and Survival of Breast Cancer Cells by Regulating Extracellular Signal-Regulated Kinase Activation.

Specific interactions between Smad proteins and AP-1 components determine TGFβ-induced breast cancer cell invasion

JUNB Governs a Feed-Forward Network of TGFβ Signaling That Aggravates Breast Cancer Invasion

Jnk/Ap-1 Pathway is Involved in Tumor Necrosis Factor-Alpha Induced Expression of Vascular Endothelial Growth Factor in Mcf7 Cells

TGFβ and EGF Signaling Orchestrates the AP-1- and P63 Transcriptional Regulation of Breast Cancer Invasiveness

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells.

C-Jun Induces Mammary Epithelial Cellular Invasion and Breast Cancer Stem Cell Expansion

Jnk and Pten Cooperatively Control the Development of Invasive Adenocarcinoma of the Prostate

JNK is Required for Maintaining the Tumor-Initiating Cell-Like Properties of Acquired Chemoresistant Human Cancer Cells.

COP1 and GSK3β Cooperate to Promote C-Jun Degradation and Inhibit Breast Cancer Cell Tumorigenesis.

Alternative Promotion and Suppression of Metastasis by JNK2 Governed by Its Phosphorylation.

Abstract 3051: JunAP, a peptide antagonist against the activator protein 1 transcription factor complex, demonstrates cancer cell cytotoxicity and reduced invasion in vitro and tumor regression in vivo in TNBC models

The JNK and Hippo pathways control epithelial integrity and prevent tumor initiation by regulating an overlapping transcriptome

C-Jun, a Crucial Molecule in Metastasis of Breast Cancer and Potential Target for Biotherapy.

Signal integration by JNK and p38 MAPK pathways in cancer development

Inhibition of Proliferation of Estrogen Receptor-Positive Mcf-7 Human Breast Cancer Cells by Tamoxifen Through C-Jun Transcription Factors

JNK Regulates Epithelial Mesenchymal Transition Induced by Transforming Growth Factor Β1 in Rat Peritoneal Mesothelial Cells

c-Jun/AP-1 overexpression reprograms ERα signaling related to tamoxifen response in ERα-positive breast cancer

Type II Cgmp-Dependent Protein Kinase Inhibits EGF-induced MAPK/JNK Signal Transduction in Breast Cancer Cells

Cancer Cell Previews 14-3-3 z Turns TGF-b to the Dark Side